NYSE:PEN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. More Details


Snowflake Analysis

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Penumbra's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: PEN's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

15.6%

PEN

-1.5%

US Medical Equipment

-1.0%

US Market


1 Year Return

42.5%

PEN

20.0%

US Medical Equipment

19.6%

US Market

Return vs Industry: PEN exceeded the US Medical Equipment industry which returned 20% over the past year.

Return vs Market: PEN exceeded the US Market which returned 19.6% over the past year.


Shareholder returns

PENIndustryMarket
7 Day15.6%-1.5%-1.0%
30 Day26.5%3.4%2.2%
90 Day6.8%7.3%11.5%
1 Year42.5%42.5%21.0%20.0%22.3%19.6%
3 Year150.1%150.1%71.3%67.0%45.3%35.7%
5 Year409.8%409.8%166.8%146.9%124.8%99.8%

Long-Term Price Volatility Vs. Market

How volatile is Penumbra's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Penumbra undervalued compared to its fair value and its price relative to the market?

13.32x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: PEN ($228.46) is trading above our estimate of fair value ($144.98)

Significantly Below Fair Value: PEN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: PEN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: PEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PEN is overvalued based on its PB Ratio (13.3x) compared to the US Medical Equipment industry average (5.1x).


Next Steps

Future Growth

How is Penumbra forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

111.6%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PEN is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: PEN is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PEN's is expected to become profitable in the next 3 years.

Revenue vs Market: PEN's revenue (17% per year) is forecast to grow faster than the US market (10.2% per year).

High Growth Revenue: PEN's revenue (17% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PEN's Return on Equity is forecast to be low in 3 years time (5.4%).


Next Steps

Past Performance

How has Penumbra performed over the past 5 years?

28.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PEN is currently unprofitable.

Growing Profit Margin: PEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PEN is unprofitable, but has reduced losses over the past 5 years at a rate of 28.7% per year.

Accelerating Growth: Unable to compare PEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PEN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.3%).


Return on Equity

High ROE: PEN has a negative Return on Equity (-2.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Penumbra's financial position?


Financial Position Analysis

Short Term Liabilities: PEN's short term assets ($590.2M) exceed its short term liabilities ($108.1M).

Long Term Liabilities: PEN's short term assets ($590.2M) exceed its long term liabilities ($82.5M).


Debt to Equity History and Analysis

Debt Level: PEN is debt free.

Reducing Debt: PEN has not had any debt for past 5 years.

Debt Coverage: PEN has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PEN has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Penumbra current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.0yrs

Average management tenure


CEO

Adam Elsesser (58 yo)

17yrs

Tenure

US$726,690

Compensation

Mr. Adam Elsesser serves as President at Penumbra, Inc. since May 2020. He Co-Founded Penumbra, Inc. in 2004 and has been its Chief Executive Officer since 2004. Mr. Elsesser has been the Chairman since Ja...


CEO Compensation Analysis

Compensation vs Market: Adam's total compensation ($USD726.69K) is below average for companies of similar size in the US market ($USD6.20M).

Compensation vs Earnings: Adam's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Adam Elsesser
Co-Founder17yrsUS$726.69k2.64%
$ 218.8m
Maggie Yuen
Chief Financial Officer1.08yrsUS$2.29m0.017%
$ 1.4m
Johanna Roberts
Executive VP2.33yrsUS$2.56m0.11%
$ 9.0m
James Pray
President of International6yrsUS$504.29k1.18%
$ 98.2m
Lynn Rothman
Executive VP & Chief Business Officer6yrsUS$605.13k0.34%
$ 28.4m
Arani Bose
Co-Founder16.58yrsUS$501.65k1.52%
$ 125.8m
Ryan Powers
Vice President of Operationsno datano datano data
Lambert Shiu
Chief Accounting Officer1.08yrsno data0.028%
$ 2.3m
David Barry
Chief Technology Officerno datano datano data
Corey Teigen
Chief Scientific Officer0.50yrno datano data
Jee Hamlyn-Harris
Investor Relations Officerno datano datano data
Kathleen Kidd
Vice President of Quality & Compliance12yrsno datano data

6.0yrs

Average Tenure

56yo

Average Age

Experienced Management: PEN's management team is seasoned and experienced (6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Adam Elsesser
Co-Founder17yrsUS$726.69k2.64%
$ 218.8m
Arani Bose
Co-Founder16.58yrsUS$501.65k1.52%
$ 125.8m
Harpreet Grewal
Independent Director5.75yrsUS$195.59k0.034%
$ 2.8m
Thomas Wilder
Independent Director4yrsUS$179.97k0.010%
$ 866.9k
Don Kassing
Presiding Independent Director5.42yrsUS$179.97k0.026%
$ 2.1m
Surbhi Sarna
Independent Director1.5yrsUS$229.90k0.0014%
$ 117.8k
Bridget O'Rourke
Independent Director3.75yrsUS$189.34k0.0079%
$ 656.2k
Janet Leeds
Independent Director2yrsUS$319.93k0.0040%
$ 331.8k

4.7yrs

Average Tenure

57yo

Average Age

Experienced Board: PEN's board of directors are considered experienced (4.7 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4%.


Top Shareholders

Company Information

Penumbra, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Penumbra, Inc.
  • Ticker: PEN
  • Exchange: NYSE
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$8.296b
  • Shares outstanding: 36.31m
  • Website: https://www.penumbrainc.com

Number of Employees


Location

  • Penumbra, Inc.
  • One Penumbra Place
  • Alameda
  • California
  • 94502
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PENNYSE (New York Stock Exchange)YesCommon StockUSUSDSep 2015
0P8DB (Deutsche Boerse AG)YesCommon StockDEEURSep 2015
PEN *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNSep 2015

Biography

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, Japan, and internationally. The company offers aspiration based thrombectomy sys...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/17 00:20
End of Day Share Price2021/01/15 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.